美股新聞 標題聯播 · 近 24 小時 348 則 · 31 個來源 · 最新 9/20 04:16
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · AMLX近 30 天 9 則 · 第 1 / 1 頁
- Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
- Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
- Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
- Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
- Oracle Stock And 2 High Growth Picks Backed By Rising Credit Demand
- Oracle Stock And 2 Growth Picks With Strong Earnings Potential
- Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
- Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
- Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
- Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
- AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
- Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise
- Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?
- Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization
- Why Amylyx Pharmaceuticals Stock Skyrocketed Today
- AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering
- Micron, Coherent, SpaceX, Klarna, Amylyx, and More Stocks That Explain Today’s Market
- A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High
- AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。